Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cessatech A/S ("Cessatech" or the "Company") today releases its results for the period 6. April - 31 December 2020. The Year-end report is available as an attached document to this press release and on www.cessatech.com under Investor, `Filings & Reports'. The company is on track with Q4 activities and getting ready for an exciting year.
- Net revenue was KDKK 0
- Operating result was KDKK -576
- Net result was KDKK -512
- Cash and bank was KDKK 13,506
- Result per share* was DKK -0,16
- Solidity** was 99%
*Result per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 December 2020 amounted to 3,680,000 shares, the average number of shares during the full-year was 1,537,721. There has been an increase in the number of shares since the completion of the IPO in December 2020, the average number of shares for Q4-2020 was 3,255,385 shares. **Solidity: Total equity divided by total capital and liability
Highlights during Q4-2020- Finalized a very successful IPO in December with an oversubscription rate of app 680%
- Finalized negotiations of preferred manufacturer for clinical and commercial batches
- Finalized Registry Study (0203) from 10 years' data in children from Karolinska University Hospital
- Submitted Fast-track US patent application for CT001
- Initiated clinical preparations of first 3 clinical activities related to CT001
"I would like to welcome all new shareholders - and acknowledge you for the strong confidence in our business, our product and us. Together with an extraordinary team, I am looking forward to transforming Cessatech closer to a phase III company - with three (3) major milestones in 2021, the clinical results of 3 studies - 2021 will be a very exciting year" Says Jes Trygved, CEO